Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Xunfei Healthcare Technology Co., Ltd.
訊飛醫療科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2506)

INSIDE INFORMATION ANNOUNCEMENT PROPOSED IMPLEMENTATION OF THE H SHARE FULL CIRCULATION BY THE COMPANY

This announcement is made by Xunfei Healthcare Technology Co., Ltd. (the "**Company**") pursuant to the Inside Information Provisions (the "**Inside Information Provisions**") under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

Reference is made to the Guidelines on Application for "Full Circulation" of Domestic Unlisted Shares of H-share Companies (《H股公司境內未上市股份申請「全流通」業務指引》) issued by the China Securities Regulatory Commission (the "**CSRC**") on November 14, 2019 and further amended on August 10, 2023 (the "**Guidelines**"), and the Trial Measures for the Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies (《境內企業境外發行證券和上市管理試行辦法》) issued by the CSRC on February 17, 2023 regarding the procedures of application for full circulation of shares by companies whose H shares are listed on the Stock Exchange for circulation of domestic unlisted shares on the Stock Exchange.

In view of the Guidelines, the board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the Company has submitted applications to the CSRC for the conversion of 35,119,645 domestic shares of the Company (the "**Unlisted Shares**") into H shares (the "**H Shares**"). Upon obtaining all relevant filings and/or approvals from the relevant regulatory authorities (including but not limited to the CSRC and the Stock Exchange) and complying with all applicable laws and regulations, such Unlisted Shares will be converted into H Shares and become eligible for listing and trading on the Main Board of the Stock Exchange. According to the Articles of Association of the Company, no further general meeting is required to be convened to approve the conversion and listing.

The relevant details are set out below:

Name of Shareholder	Number of domestic shares proposed to be converted into H Shares	Approximate percentage of the domestic shares proposed to be converted in the total issued share capital of the Company
iFlytek Co., Ltd.	21,407,596	17.7101%
Hefei Zhengsheng Information Technology Partnership (Limited Partnership) (合肥正昇信息科技合夥企業(有限合夥))	9,736,647	8.0549%
Gongqingcheng Jizhi Equity Investment Partnership (Limited Partnership) (共青城集智股權投資合夥企業(有限合夥))	1,044,000	0.8637%
Hainan Shuiyao Enterprise Management Consulting Services Co., Ltd. (海南水遙企業管理諮詢服務有限責任公司)	900,000	0.7446%
Anhui Yanzhi Technology Co., Ltd. (安徽言知科技有限公司)	676,829	0.5599%
Gongqingcheng Huizhi Yuntong Equity Investment Partnership (Limited Partnership) (共青城匯智耘通股權投資合夥企業(有限合夥))	525,000	0.4343%
iFlytek Haihe (Tianjin) AI Venture Capital Fund Partnership (Limited Partnership) (訊飛海河(天津)人工智能創業投資基金合夥企業(有限合夥))	476,524	0.3942%
Hainan Yuema Zhengchun Venture Capital Center (Limited Partnership) (海南躍馬爭春創業投資中心(有限合夥))	203,049	0.1680%
Hefei Kexun Lianshan Innovation Industry Investment Fund Partnership (Limited Partnership) (合肥科訊連山創新產業投資基金合夥企業(有限合夥))	150,000	0.1241%
Total	**35,119,645**	**29.0537%**

Note: Due to rounding, the sum of individual percentages may not equal the total percentage shown.

The Company will make further announcement(s) on the progress and details of the full circulation of H Shares and the conversion and listing in due course in accordance with the Inside Information Provisions and/or the requirements of the Listing Rules.

The full circulation of H Shares and the completion of the conversion and listing are subject to other relevant procedures as required by the CSRC, the Stock Exchange and other relevant domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Xunfei Healthcare Technology Co., Ltd.
Dr. Tao Xiaodong
Executive Director

Hong Kong, November 2, 2026

As at the date of this announcement, the Board of the Company comprises: (i) Dr. Tao Xiaodong as executive director; (ii) Dr. Liu Qingfeng, Mr. Zhao Zhiwei and Mr. Duan Dawei as non-executive directors; and (iii) Prof. Wang Yang, Prof. Zhao Huifang and Mr. Tan Ching as independent non-executive directors.